Medigene AG launches capital increase with subscription rights and backstop agreement

  • Issue of up to 4,912,531 new shares
  • Backstop agreement in place with commitment of up to EUR 3 million

Planegg/Martinsried, April 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported that per its ad hoc announcement on April 22, 2024, the Company will be launching a capital raise with subscription rights, and expects gross proceeds of approximately EUR 5.9 million gross.

Members of Medigene AG’s management and Supervisory Board intend to subscribe for new shares as part of the rights offering and the private placement. Within the framework of a backstop agreement, an investor has declared his commitment to Medigene to acquire unsubscribed new shares in an amount of up to EUR 3 million.

“This capital increase will strengthen our financial position and enable Medigene to advance its corporate strategy to develop our differentiated T cell receptor engineered T cell (TCR-T) therapies,  and also pursue new partnerships to expand our End-to-End Platform into TCR-based therapies such as T cell engagers (TCE) and TCR-Natural Killer therapies,” said Selwyn Ho, CEO of Medigene AG. “The funds will also allow us to progress work for the clinical development of our lead program, MDG1015. Following recent positive EU and US preliminary regulatory interactions, we remain on track for an IND/CTA approval in the second half of 2024.”

The Company resolved to increase its share capital from EUR 24,562,658.00 by up to EUR 4,912,531.00 to up to EUR 29,475,189.00 by issuing up to 4,912,531 new no-par value registered shares with a pro rata amount of the share capital of EUR 1.00 and with full dividend rights from January 1, 2023.

The new shares will be offered to all shareholders for subscription. Over-subscription is permitted. Any unsubscribed new shares will be offered for purchase by way of a private placement to investors within the European Union. The subscription ratio is set at 5:1, i.e. five (5) old shares entitle the subscription to one (1) new share. Organized trading of subscription rights will be arranged. The subscription price for both the exercise of subscription rights and the private placement is EUR 1.20. The subscription period for the new shares begins on April 24, 2024 at 0:00 hours (CEST) and ends on May 7, 2024 at 24:00 hours (CEST). The new shares are to be admitted to trading on the Frankfurt Stock Exchange (Prime Standard) after they are issued. The capital increase will not require a prospectus.

Details of the rights offering will be published in the Federal Gazette today, on April 23, 2024. Following the publication in the Federal Gazette, information on the capital increase will also be available on the Company’s website

The technical execution of the capital increase is supported by Baader Bank AG. CapSolutions GmbH and MC Services AG act as contacts for institutional investors and are jointly responsible for the placement.

—  end of press release  —


About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information, please visit. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01


In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.